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Abstract
By September 2013, war between Sudan and South Sudan resulted in >70,000 Sudanese refugees 
and high pneumonia incidence among the 20,000 refugees in Yida camp, South Sudan. Using 
Médecins Sans Frontières (MSF)-provided data and modifying our decision-tree models, we 
estimated if administering Haemophilus influenzae type b (Hib)-containing (pentavalent vaccine, 
also with diphtheria pertussis and tetanus [DPT] and hepatitis B) and pneumococcal conjugate 
(PCV) vaccines were cost-effective against hospitalized pneumonia. Among children <2 years old, 
compared with no vaccination, one- and two-doses of combined Hib-containing and PCV would 
avert an estimated 118 and 125 pneumonia cases, and 8.5 and 9.1 deaths, respectively. The cost 
per Disability-Adjusted-Life-Year averted for administering combined one- and two-doses was US
$125 and US$209, respectively. MSF demonstrated that it was possible to administer these 
vaccines during an emergency and our analysis found it was highly costeffective, even with just 
one-dose of either vaccine. Despite unknown etiology, there is strong field and now economic 
rationale for administering Hib and PCV during at least one humanitarian emergency.
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1. Introduction
War has occurred between South Sudan and Sudan for decades and continues today despite 
the 2011 independence, which was expected to bring stability to the country. On 2 August 
2012, an international health non-governmental organization, Médecins Sans Frontières 
(MSF), announced a health catastrophe for Yida camp, in northern South Sudan because of 
increasing arrivals of Sudanese refugees from across the border, overstretched camps, and 
the high numbers of children with malnutrition, who were further weakened by diarrhea, 
malaria and respiratory infections [1]. Black et al. (2010) found that pneumonia and diarrhea 
are the leading causes of childhood deaths globally and the major causes of lower 
respiratory-associated or pneumonia deaths are Haemophilus influenzae type b (Hib) and 
Streptococcus pneumoniae [2]. Through the end of 2012 in Yida camp, respiratory 
infections continued and even increased for acute respiratory infections (ARI) among 
outpatients. Therefore, MSF prepared in the ensuing months to vaccinate against Hib and 
Streptococcus pneumoniae with all training and logistics completed and the vaccine finally 
arriving the first of July 2013 to provide three rounds each of Hib and pneumococcal 
conjugate (PCV) vaccines. From their data reported December 2013, we performed a cost-
effectiveness analysis from the perspective of MSF [3].
2. Methods
Using the MSF data (Table 1), we used our previously developed decision-tree models (Fig. 
1) for one- and two-dose Hib-containing and PCV vaccinations separately and in 
combination to estimate the vaccines’ impact and cost-effectiveness following the target 
population in their first 2 years of life [4]. We did not include indirect non-medical costs as 
the MSF report provided neither indirect costs, e.g., time lost to parents, nor non-medical 
costs, e.g., transportation.
From the MSF report using estimates provided from the United Nations High Commissioner 
for Refugees (UNHCR), the mid-2012 total population was 20,000 [3]. Given 585 persons 
were hospitalized with ARI [3], presumptively mainly pneumonia, the annual incidence was 
2925/100,000 total population. This rate would be higher among young children; however, is 
similar to double the estimated African childhood Hib pneumonia incidence (3448/100,000 
children aged <5 years) [5]. Doubling the reported childhood Hib incidence was done 
because of the high degree of malnutrition and overcrowding, inadequate shelter and 
blankets during a humanitarian emergency [4]. Comparing the annual African childhood Hib 
pneumonia rate, pneumococcal pneumonia has double the incidence [6]. Therefore, the 
childhood pneumococcal pneumonia incidence was assumed to be 5850/100,000 children 
aged <5 years (Table 1). Invasive disease, such as meningitis or sepsis, was not considered. 
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Table 1 provides other MSF report data for target population, vaccine coverage/wastage, and 
vaccination program costs that were used.
We assumed 75% of children would use healthcare services. Vaccine effectiveness data for 
South Sudan were unavailable. From a Gambian study, Hib vaccine efficacy against 
radiologically defined pneumonia was 22.4% (95% confidence interval [95%CI] 1.9–38.6) 
[7]; we assumed one-dose efficacy was 20% [3]. From another Gambian trial, two-dose PCV 
efficacy against clinical or severe clinical pneumonia was 37% (95% CI 25–48) [8]; one-
dose was assumed to be 29% [3].
We used World Health Organization (WHO) estimates for Africa-specific childhood case 
fatality rates (CFR) for Hib and pneumococcal pneumonia [5,6]. Because Hib and 
pneumococcal CFRs were similar we used one rate. We estimated the medical visit cost at 
US$1.01/day using the average cost for Ethiopia and Kenya— neighboring countries [9] and 
multiplied it by the average stay of 4 days [10]. Medication costs ($12.34)/pneumonia case 
were estimated from previous reports (Table 1) [11].
We compared the costs and benefits of the July-September 2013 MSF conducted Hib-
containing and PCV campaigns under base-case scenarios: (1) no vaccination, (2–5) one- 
and two-dose Hibcontaining vaccine or PCV, and (6–7) one-dose or two-doses of combined 
Hib-containing vaccine and PCV using Microsoft® Excel 2010 (Redmond, WA). We 
estimated the incremental cost-effectiveness ratio (ICER) as cost per Disability-Adjusted-
Life-Year (DALY) averted expressed in 2013 US dollars. DALYs used were WHO life 
expectancy data weighted by years lost and disability from pneumonia, with the mean 
duration of four hospital-days and no long-term sequel among survivors [12]. To determine 
if intervention was cost-effective, we used the WHO threshold for highly cost-effective 
intervention of less than the country’s gross domestic product (GDP)/capita vs. the cost/
DALY averted [13]; South Sudan 2013 GDP/capita was US$1045 [14].
A one-way sensitivity analysis was conducted to evaluate the impact of changing values of 
several parameters on ICER for two-doses of each vaccine or both vaccines combined (Table 
1). These one-way sensitivity analyses were examined using tornado diagrams. A threshold 
analysis was done to decipher the break-even price of two-doses of Hib-containing and PCV 
vaccines when all other variables are held at their base-case value. Finally, a probabilistic 
sensitivity analysis (PSA) was done on those variables that indicated an impact on the cost 
result after performing the one-way sensitivity analysis. This allowed us to limit the number 
of variables selected for this analysis. Up to 5000 iterations were performed to obtain the 
cost distribution results. All future costs and DALY estimates were discounted at an annual 
rate of 3%.
3. Results
Tables 2 and 3 summarize all findings. For no vaccination, estimated total pneumonia cases 
and associated deaths were 507 and 37, respectively, with 380 medical visits costing US
$6232.
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One-dose and two-dose Hib-containing vaccination prevented an estimated 30 and 33 Hib 
pneumonia cases, and estimated 2 and 3 deaths, respectively while reducing medical costs 
by approximately US$400 for each scenario (Table 2). One- and two-dose PCV would avert 
an estimated 98 and 105 pneumococcal pneumonia cases, and estimated 7 and 8 deaths 
averted, respectively. For one- and two-dose PCV, the medical cost averted was about $1100 
and $1300, respectively. The greatest impact was seen with combined one- and two-doses of 
Hib-containing and PCV; they averted 118 and 125 pneumonia cases, and 8.5 and 9.1 
deaths, respectively with the largest medical cost reductions of approximately US$1500 for 
each scenario.
Table 3 shows administering one- and two-doses of Hib-containing vaccines yield ICER/
DALY averted of US$211 and US $310, while costing US$945 and US$1388 per case 
averted, respectively. One- and two-doses of PCV yield ICER/DALY averted of US $148 
and US$210, respectively and $664 and $942, respectively, for cost per case averted. The 
combined one- and two-doses of Hib-containing and PCV campaigns would yield ICER/
DALY averted of US$125 and US$209, respectively and $559 and $936, respectively, for 
cost per case averted. Therefore given the South Sudan 2013 GDP/capita of US$1045, all six 
scenarios had a cost/DALY averted ranging from $125 (one-dose combined vaccines) to 
$310 (2 doses of PCV) that are highly cost-effective.
In one-way sensitivity analysis, the base-case estimates for the two-doses of each or 
combined vaccines were most affected by vaccine efficacy, disease burden of the bacteria 
prevented, and CFR. The greatest range of costs/DALY averted was seen for two-doses Hib: 
$199–$1025 for lower and upper sensitivity limits for vaccine efficacy of 1.9–38.6% and 
$245.27–$416.80 for lower and upper limit for Hib disease burden of 2194–3656/100,000 
children. No other analyses ranged by greater than $135 for cost/DALY averted (Fig. 2).
Although the cost of the vaccine was known, Fig. 3 presents how cost-effectiveness of each 
vaccine varies as the unit price of vaccines are varied up to $100. Using the threshold cost-
effectiveness of GDP per capita ($1045 in US$ for 2013), Hib-containing vaccine would be 
considered very cost-effective until a unit price of $25 and cost-effective up to a unit price of 
$80. PCV vaccine would be considered very cost-effective up to a unit price of $85.
Fig. 4 represents the probabilistic sensitivity analyses for 2- doses of Hib-containing vaccine 
(Fig. 4A) and PCV (Fig. 4B). For 2-doses of Hib-containing vaccine the maximum DALYs 
averted was 801 with a mean of 31. For 2-doses of PCV the maximum DALYs averted was 
1090 with a mean of 85.
4. Discussion
In humanitarian emergencies, excess communicable disease-associated morbidity and 
mortality, including pneumonia, are avoidable. Effective vaccines exist but are rarely 
administered. Using MSF data for Hib-containing and pneumococcal vaccinations, we found 
administration highly cost-effective even with one-dose of either vaccine for children in their 
first 2 years of life when examining cost/DALY averted [15]. Hib and pneumococcus are 
important causes of childhood bacterial meningitis, too; these vaccines can also prevent 
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meningitis [7,8], likely making them more even cost-effective than this analysis showed. 
Post-immunization evaluation and continued surveillance for ARI/pneumonia remain critical 
and will help to determine if these vaccines have been successful in lowering the ARI rates 
and related causes of morbidity and mortality.
We used conservative rates for Hib and pneumococcal pneumonia (MSF-provided total ARI 
inpatient figures); our prior study doubled the childhood African incidence because of the 
level of malnutrition, overcrowding, and inadequate shelter during an emergency. 
Additionally, MSF cost of vaccines was more than Global Alliance for Vaccines and 
Immunization (GAVI Alliance)- supplied vaccines increasing the cost-side of model.
Similar to other studies, we found vaccine efficacy, CFR, and disease burden had the greatest 
influence on the cost-effectiveness [16,17]. Although MSF provided much information, we 
used sensitivity analyses for many estimates—disease burden; duration, use and outcome of 
healthcare; and vaccine efficacies—these analyses still showed the costs/DALY adverted 
was less than South Sudan’s GDP/capita.
Although, WHO/Strategic Advisory Group of Experts (SAGE) on Immunization framework 
for decision-making of vaccination in acute humanitarian emergencies has been developed, 
until recently measles has been the only vaccine administered in humanitarian emergencies 
[18,19]. The three steps for this framework have been met for Hib and PCV through MSF’s 
experience in Yida camp: the ARI risk is high; the vaccines exist, are safe and amenable to 
giving in mass campaigns or as part of routine immunization; and they can be administered 
in a humanitarian setting [19]. GAVI-Alliance needs to consider supporting administration 
of Hib and PCV for children in emergency settings now that we know it is feasible to 
provide these life-saving immunizations to these most vulnerable young people. ARI data 
during humanitarian emergencies are limited; few studies examined morbidity and even 
fewer the specific pathogens [20]; but in developing countries, Hib and pneumococcus are 
the most frequent causes of bacterial pneumonia. Therefore, despite a lack of etiology there 
is strong field and now economic rationale for administering Hib and PCV during at least 
one humanitarian emergency.
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Tornado diagrams of univariate sensitivity analysis. (A) 2 doses of Hib-containing vaccine, 
(B) 2 doses of PCV vaccine, and (C) 2 dose Hib/2 dose PCV vaccine.
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Cost-effective threshold analysis by vaccine price. Vaccine unit price varied up to $100 with 
the threshold cost-effectiveness ratio at the lower horizontal line based on South Sudan’s 
GDP per capita and at the upper horizontal line based on three times that GDP per capita.
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Probabilistic Sensitivity Analysis. (A) 2-doses Hib-containing vaccine. (B) 2-doses PCV. 
DALY, disability-adjusted life year lost.
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Table 1
2013 supplemental immunization activity of MSF, Yida refugee camp, South Sudan.
Parameter Base-case estimate Sensitivity range References
Target population 5781 NA [3]
Epidemiologic
 Hib pneumonia rate (per 100,000, annual) 2925 2194–3656 (±25%) [3,5]
 Pneumococcal pneumonia rate (per 100,000, annual) 5850 4388–7313 (±25%) Doubled Hib
[5,6]
Clinical
 Children’s healthcare utilization, % 75 94–56 (±25%) Assumption
 Vaccine coverage per survey, %
  1 dose 89.2 NA [3]
  2 doses 66.1 NA [3]
Hib vaccine efficacy for radiologically defined pneumonia,%
  1 dose 20.0 0.5–25.0 (+25%) Assumption
[4]
  2 doses 22.4 1.9–38.6 [7]
PCV vaccine efficacy for clinical or severe clinical pneumonia, %
  1 dose 29.0 0.5–36.25 (+25%) Assumption
[4]
  2 doses 37.0 25.0–48.0 [8]
Case Fatality Rate (CFR, aged < 5 years), %
  Care 6 4–8 [5,6]
  No care 11 7–18 [5,6]
Length of inpatient stay, days 4 3–6 [10]
Vaccine wastage (%) 1 NA [3]
Economic, US$
  Hib vaccine price/dose 2.10 NA [3]
  PCV price/dose 7.97 NA [3]
  Cost/dose delivered, excluding expatriate staff 3.45 NA [3]
  Total care cost/day 1.01 NA [9]
  Medication costs/case of pneumonia 12.34 NA [11]
Costs were adjusted to 2013 levels.
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Table 2
Impact of Hib-containing and PCV vaccination program on total pneumonia events among children aged <2 
years, Yida refugee camp, South Sudan, 2013.
Events Number of events (Lower Limit [LL]-Upper L [UL]) Averted (LL-UL)
Without vaccination program
 Cases 507 (423–507) –
 Deaths 37 (29–46) –
 Number of DALYs 2274 (1804–2823) –
 Medical visits 380 (284–477) –
 Medical costs (US$) 6232 (5194–7271) –
1 dose Hib vaccination program
 Cases 477 (393–562) 30 (1–38)
 Deaths 35 (34–37) 2 (0–3)
 Number of DALYs 2139 (1697–2655) 135 (3–169)
 Medical visits 358 (448–267) 23 (17–28)
 Medical costs (US$) 5861 (4376–7346) 371 (9–463)
 Vaccination costs (US$) 29,192 – –
 Total costs (US$) 35,053 (33,568–36,538) –
2 dose Hib vaccination program
 Cases 474 (390–559) 33 (25–41)
 Deaths 34 (27–42) 3 (2–4)
 Number of DALYs 2127 (1687–2640) 147 (45–229)
 Medical visits 356 (266–446) 25 (7–38)
 Medical costs (US$) 5828 (4352–7305) 403 (122–626)
 Vaccination costs (US$) 50,824 – –
 Total costs (US$) 56,652 (50,824–58,129) –
1 dose PCV vaccination program
 Cases 487 (398–506) 98 (2–109)
 Deaths 30 (24–38) 7 (0–8)
 Number of DALYs 1882 (1493–2336) 392 (7–490)
 Medical visits 315 (235–395) 66 (1–87)
 Medical costs (US$) 5157 (3851–6464) 1075 (19–1347)
 Vaccination costs (US$) 60,067 – –
 Total costs (US$) 65,224 (63,917–66,530) –
2 dose PCV vaccination program
 Cases 402 (344–460) 105 (78–132)
 Deaths 29 (23–36) 8 (6–10)
 Number of DALYs 1802 (1492–2237) 472 (352–586)
 Medical visits 301 (235–395) 79 (49–99)
 Medical costs (US$) 4937 (3687–6188) 1294 (965–1622)
 Vaccination costs (US$) 104,579 – –
 Total costs (US$) 109,516 (108,801–110,231) –
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Events Number of events (Lower Limit [LL]-Upper L [UL]) Averted (LL-UL)
1 dose Hib/1 dose PCV vaccination program
 Cases 390 (327–505) 118 (2–147)
 Deaths 28 (22–37) 8.5 (0–11)
 Number of DALYs 1747 (1386–2264) 528 (10–659)
 Medical visits 292 (225–379) 88 (2–111)
 Medical costs (US$) 4787 (3574–6204) 1445 (28–1811)
 Vaccination costs (US$) 71,112 – –
 Total costs (US$) 75,899 (74,686–77,316) –
2 dose Hib/2 dose PCV vaccination program
 Cases 382 (324–440) 125 (99–151)
 Deaths 28 (22–34) 9.1 (7–11)
 Number of DALYs 1713 (1359–2126) 561 (443–697)
 Medical visits 287 (214–359) 94 (70–118)
 Medical costs (US$) 4694 (3505–5883) 1538 (1148–1928)
 Vaccination costs (US$) 122,595 – –
 Total costs (US$) 127,289 (126,100–128,478) –
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